echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Johnson & Johnson Imbruvica combined with Roche Venclexta successfully treats CLL/SLL Phase III clinical trial

    Johnson & Johnson Imbruvica combined with Roche Venclexta successfully treats CLL/SLL Phase III clinical trial

    • Last Update: 2021-06-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compileriver

    On June 14th, according to foreign media reports, Johnson & Johnson’s Imbruvica combined with Roche’s Genentech’s Venclexta (venetoclax) succeeded in a phase III GLOW study, which evaluated the combination therapy as a chronic disease in the elderly or in poor health.


    The study conducted by Johnson & Johnson subsidiary Janssen compared Imbruvica+Venclexta combination therapy with chlorambucil + obinutuzumab (Clb+O) in this patient population


    Imbruvica and Venclexta have complementary mechanisms of action


    GLOW's data shows that the oral combination therapy of Imbruvica and venetoclax once a day for a fixed duration is better than standard chemotherapy and immunotherapy.


    In addition to the GLOW phase III study, Janssen also announced that the phase III MAIA study evaluated the overall survival (OS) of Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd) over the use of Rd alone


    Reference source: Janssen Hits Two Phase III Marks in Hematology Presentations at EHA

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.